🧬 #Sonrotoclax aprobado en China.
💊 Para #LLC, #LLP y #LCM.
Tras tratamiento previo con inhibidores de BTK.
➡️ Nueva opción terapéutica.

📎 Más información: dengyuemed.com/product/baiy...
📧 info@dengyuemed.com

#Baoyueda #Linfomas #Leucemia #Recaída #Refractario #BCL2 #DengYueMedicinasEnHongKong

#ASH25 The BCL2 inhibitor #sonrotoclax produced good responses in patients with treatment-naïve CLL/SLL when combined with #obinutuzumab, with ORRs of 89% across all patients and 93% at a 320 mg dose: https://ow.ly/M8uB50XF6zT
#HemeSky #MedSky